Insider Stock Trading History of Novartis Ag


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Novartis Ag since year 2005. The trader's CIK number is 1114448. At the time of this reporting, Novartis Ag is the 10% Owner of Aileron Therapeutics Inc . (stock ticker symbol ALRN). See this page for all insider trading activities at Aileron Therapeutics Inc .

Note that in the past NOVARTIS AG also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Novartis Ag since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-07-05 ALRN Aileron Therapeutics Inc Buy 266,667 15.00 4,000,005
2017-06-19 RARX Ra Pharmaceuticals, Inc. Sale 3,220 22.02 70,897
2017-06-16 RARX Ra Pharmaceuticals, Inc. Sale 53,200 21.25 1,130,234
2017-06-08 RARX Ra Pharmaceuticals, Inc. Sale 700 22.00 15,400
2017-06-06 RARX Ra Pharmaceuticals, Inc. Sale 7,274 22.98 167,163
2017-06-07 RARX Ra Pharmaceuticals, Inc. Sale 4,840 22.11 106,997
2017-06-02 RARX Ra Pharmaceuticals, Inc. Sale 14,867 23.47 348,943
2017-06-05 RARX Ra Pharmaceuticals, Inc. Sale 4,780 23.11 110,489
2017-06-01 RARX Ra Pharmaceuticals, Inc. Sale 10,722 23.89 256,180
2017-05-31 RARX Ra Pharmaceuticals, Inc. Sale 35,539 23.94 850,910
2017-05-25 RARX Ra Pharmaceuticals, Inc. Sale 53 25.00 1,325
2017-05-26 RARX Ra Pharmaceuticals, Inc. Sale 5,300 25.14 133,268
2017-05-24 RARX Ra Pharmaceuticals, Inc. Sale 17,451 25.00 436,362
2017-05-18 RARX Ra Pharmaceuticals, Inc. Sale 9,019 25.50 229,966
2017-05-16 RARX Ra Pharmaceuticals, Inc. Sale 20,081 26.33 528,732
2017-05-17 RARX Ra Pharmaceuticals, Inc. Sale 22,534 25.51 574,909
2017-02-28 RARX Ra Pharmaceuticals, Inc. Sale 7,847 20.86 163,672
2017-02-27 RARX Ra Pharmaceuticals, Inc. Sale 57,844 20.96 1,212,294
2017-02-24 RARX Ra Pharmaceuticals, Inc. Sale 5,398 20.93 113,001
2017-02-23 RARX Ra Pharmaceuticals, Inc. Sale 4,999 21.04 105,158
2017-02-22 RARX Ra Pharmaceuticals, Inc. Sale 749 21.86 16,369
2017-03-01 RARX Ra Pharmaceuticals, Inc. Sale 7,778 20.91 162,661
2017-03-15 NONE Aerpio Pharmaceuticals, Inc. Buy 560,000 5.00 2,800,000
2016-10-31 RARX Ra Pharmaceuticals, Inc. Buy 84,615 13.00 1,099,995
2016-10-31 RARX Ra Pharmaceuticals, Inc. Sale 339 13.00 4,407
2016-05-11 NTLA Intellia Therapeutics, Inc. Buy 277,777 18.00 4,999,986
2016-04-12 AGLE Aeglea Biotherapeutics, Inc. Buy 300,000 10.00 3,000,000
2016-02-17 PTI Proteostasis Therapeutics, Inc. Buy 375,000 8.00 3,000,000
2015-07-15 TKAI Tokai Pharmaceuticals Inc Sale 3,566 14.26 50,844
2015-07-13 TKAI Tokai Pharmaceuticals Inc Sale 20,611 14.20 292,717
2015-07-14 TKAI Tokai Pharmaceuticals Inc Sale 27,861 14.41 401,477
2015-06-16 TKAI Tokai Pharmaceuticals Inc Sale 1,120 14.27 15,982
2014-06-15 TKAI Tokai Pharmaceuticals Inc Sale 14,777 14.20 209,833
2015-06-12 TKAI Tokai Pharmaceuticals Inc Sale 5,919 14.20 84,049
2015-06-11 TKAI Tokai Pharmaceuticals Inc Sale 27,875 14.20 395,825
2015-03-18 TKAI Tokai Pharmaceuticals Inc Sale 3,000 14.50 43,500
2015-03-19 TKAI Tokai Pharmaceuticals Inc Sale 46,141 14.50 669,044
2014-09-22 TKAI Tokai Pharmaceuticals Inc Buy 325,000 15.00 4,875,000
2011-01-25 MRNA Nastech Pharmaceutical Co Inc Sale 93,005 1.14 105,932
2011-01-26 MRNA Nastech Pharmaceutical Co Inc Sale 74,500 1.15 85,302
2011-01-24 MRNA Nastech Pharmaceutical Co Inc Sale 72,800 1.19 86,704
2011-01-21 MRNA Nastech Pharmaceutical Co Inc Sale 69,500 1.26 87,917
2011-01-19 MRNA Nastech Pharmaceutical Co Inc Sale 42,800 1.54 65,869
2011-01-20 MRNA Nastech Pharmaceutical Co Inc Sale 45,700 1.32 60,552
2011-01-20 MRNA Nastech Pharmaceutical Co Inc Sale 5,700 1.48 8,407

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Novartis Ag (10% Owner of Aileron Therapeutics Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.